Pro Medicus H1 FY26 Results: Strong US Growth
Pro Medicus’ H1 FY26 results delivered strong revenue and profit growth, margin expansion to 73%, and a higher interim dividend. Despite recent share price weakness, the results validate the bullish outlook for PME shares and reinforce the company’s dominant position in US…
Pro Medicus H1 FY26 Results: Key Takeaways for Investors Pro Medicus (ASX: PME) delivered a standout H1 FY26 result, reinforcing its reputation as one of the highest-quality growth businesses on the ASX. While headline reported profit was boosted by investment gains, the underlying operational performance — the key driver of valuation — was strong across revenue, margins, and cash generation. For investors assessing the outlook for PME shares, the result confirms that recent share price weakness was driven more by macro and AI-related sentiment than by any deterioration in fundamentals. Strong Revenue Growth Driven by the US Market Pro Medicus reported H1 FY26 revenue of $124.8 million, up 28.4% year-on-year, driven primarily by continued expansion in the US healthcare imaging market. This growth reflects ongoing contract wins, increased usage across existing customers, and the scalability of the Visage platform. Underlying profit before tax rose 29.7% to $90.7 million, broadly in line with revenue growth, demonstrating that the business continues to scale efficiently without sacrificing margins. This operational leverage remains one of Pro Medicus’ defining strengths. Reported NPAT Inflated by Investment Gains — Focus on Underlying Earnings Reported NPAT surged 230.9% to $171.2 million, but this figure includes $149.1 million in unrealised gains on financial assets. While this materially strengthens the balance sheet, it is not reflective of core operating earnings. From an investment perspective, the key number remains the $90.7 million underlying PBT, which better represents the sustainable earnings power of the business. Analysts and long-term investors are likely to look through the reported profit spike and anchor valuations to underlying growth and margins. Margin Expansion Reinforces Competitive Moat Underlying EBIT margins expanded to 73%, up from 72% in HY25. In a market increasingly focused on cost pressure and AI-related disruption, this margin expansion is a critical signal. It confirms: Strong pricing power High operating leverage Minimal incremental cost to scale This performance aligns with broker commentary describing Pro Medicus as a “best-in-class” healthcare software platform and counters concerns that AI adoption would compress margins. Balance Sheet Strength and Dividend Growth Pro Medicus ended the half with $221.8 million in cash and financial assets, remains debt-free, and increased its interim dividend to 32.0 cents per share (fully franked) — a 28% increase year-on-year. Based on historical seasonality, the interim dividend implies a potential full-year dividend of ~70–80 cents, broadly consistent with consensus forecasts of 75–83 cents. This dividend growth signals management confidence in future cash flow and contract visibility. Analyst Sentiment Turns More Constructive The H1 FY26 result largely validates recent broker upgrades: Morgan Stanley (Overweight, $350 target): Sees valuation support following operational execution. Citi (Buy, $350 target): Highlights robust margins and platform strength. Bell Potter (Buy, $320 target): Points to continued US contract momentum. Morgans & Macquarie: Both upgraded ahead of results, citing undervaluation and resilience to AI disruption. Importantly, the stock was down ~16% year-to-date prior to results, suggesting the market had already priced in overly pessimistic assumptions. Actionable Investment Decisions for PME Investors 1. Long-Term Growth Investors: Accumulate on Volatility The combination of ~30% revenue growth, expanding margins, and a debt-free balance sheet supports a long-term growth thesis. Periods of tech-led volatility may offer attractive entry points. 2. Income-Aware Investors: Don’t Ignore PME While not a high-yield stock, consistent dividend growth and strong free cash flow make PME increasingly relevant for quality income-growth portfolios. 3. Risk Management: Focus on Underlying Metrics Investors should anchor valuation to underlying earnings and contract momentum, not reported NPAT inflated by investment gains.
Read on MPC Markets Mosaic
